Elaheh S. Hosseini
Advancing ovarian cancer research through cancer immunotherapy
Elaheh S. Hosseini is a PhD candidate in the Cellular and Molecular Pharmacology Program at the Rutgers Cancer Institute of New Jersey. She began her doctoral training in 2021 and joined the Payne Laboratory in 2022, where she has established a research trajectory at the interface of cancer biology and tumor immunology. Her long-term objective is to become an independent investigator dedicated to advancing the mechanistic understanding and therapeutic application of cancer immunotherapy. Her research has been recognized through support from the highly competitive NIH/NCI F99/K00 Predoctoral-to-Postdoctoral Transition Award.
Elaheh’s current work focuses on high-grade serous ovarian cancer, a clinically aggressive malignancy for which effective therapeutic options remain limited. The central aim of her F99/K00 project is to define how BLTP3A, a tumor cell–intrinsic stress-response regulator, contributes to immune evasion within the tumor microenvironment. Her findings indicate that disruption of BLTP3A function is associated with enhanced infiltration of cytotoxic T lymphocytes and a reprogramming of macrophage polarization from pro-tumor to anti-tumor states, collectively shifting the immune landscape toward tumor-restrictive activity and improving survival in preclinical models. By elucidating the signaling networks governed by BLTP3A, her work seeks to uncover therapeutic vulnerabilities that may enable the conversion of immunologically “cold” ovarian tumors into more inflamed, treatment-responsive “hot” tumors.
Her scholarship has received recognition at major scientific venues. Elaheh has presented her research at the Joint Rutgers Cancer Institute and Ludwig Princeton Symposia in 2023 and 2025, the AACR 15th Biennial Ovarian Cancer Research Symposium, the Rivkin Ovarian Cancer Symposium in 2024, and the American Association of Immunologists Annual Meeting in 2025, where she received the AAI Trainee Abstract Award. At Rutgers, she has also presented in the Trainee Seminar Series for three consecutive years.
Beyond her experimental work, Elaheh has engaged thoughtfully with the broader process of scientific career development. She describes the F99/K00 application process as rigorous and formative, in part because it requires applicants not only to articulate a compelling research plan but also to define a coherent vision for long-term scientific growth. Preparing the application helped her refine her research identity, align her doctoral training with future postdoctoral goals, and identify the conceptual and technical skills necessary for her next stage of development. She encourages fellow trainees to begin early, seek guidance from recent awardees, and frame their applications as an integrated narrative of scientific progression.
Elaheh also emphasizes the importance of mentorship in shaping her trajectory. She credits Dr. Kyle Payne with fostering a laboratory environment that balances intellectual rigor with creativity, while actively encouraging trainees to pursue opportunities that expand both their technical expertise and scientific impact. This mentorship, together with the broader research environment at the Rutgers Cancer Institute, has reinforced her commitment to a career as an independent investigator in cancer immunotherapy.
Her recent Research Café presentation exemplified this trajectory. In that talk, she presented early evidence showing that BLTP3A knockout in ovarian cancer models enhances CD8⁺ T-cell infiltration and effector function, resulting in improved survival. She also discussed data supporting BLTP3A as a candidate effector of conjugation of ATG8 to single membranes (CASM) involved in lysosomal regulation, thereby suggesting a mechanistic link between tumor-intrinsic stress pathways and immune exclusion. Among the most compelling directions of her current work is the effort to define the BLTP3A interactome and to map the spatial reorganization of immune cell populations within the tumor microenvironment following loss of this cancer cell–intrinsic stress regulator. These studies may reveal new mechanistic insights and therapeutic opportunities in ovarian cancer.
Elaheh further underscores the importance of clear and effective scientific communication. She notes that training in science communication has strengthened her ability to adapt complex ideas for diverse audiences without sacrificing precision. Her advice to fellow graduate students is to communicate with clarity, purpose, and confidence, and to anchor every presentation in two central questions; why does this matter, and what is the overarching idea?
The intellectual depth, persistence, and translational vision that characterize outstanding doctoral research is evident in Elaheh’s work. As she continues to investigate the mechanisms underlying immune evasion in ovarian cancer, she is building a strong foundation for a future career devoted to the advancement of cancer immunotherapy.